Pharsight

Napo Pharms Inc patents expiration

1. Mytesi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8574634 NAPO PHARMS INC Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions
Jan, 2018

(6 years ago)

US7323195 NAPO PHARMS INC Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
Jun, 2018

(5 years ago)

US7341744 NAPO PHARMS INC Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer
Jun, 2022

(1 year, 10 months ago)

US8962680 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea
Oct, 2031

(7 years from now)

US9585868 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea
Oct, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 31, 2017

Drugs and Companies using CROFELEMER ingredient

NCE-1 date: 31 December, 2016

Market Authorisation Date: 31 December, 2012

Treatment: Symptomatic relief of non-infectious diarrhea

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

MYTESI family patents

Family Patents